These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36343065)

  • 21. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
    Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
    Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between response to lusutrombopag and splenic volume.
    Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
    World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
    Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.
    Brown RS; Imawari M; Izumi N; Osaki Y; Bentley R; Ochiai T; Kano T; Peck-Radosavljevic M
    JHEP Rep; 2021 Apr; 3(2):100228. PubMed ID: 33644726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
    Furuichi Y; Takeuchi H; Uojima H; Atsukawa M; Arai T; Arase Y; Kako M; Hidaka H; Itoi T
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):439-448. PubMed ID: 34953107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
    Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
    Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
    Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.
    Sasaguri T; Hirakawa N; Uemura S
    JA Clin Rep; 2018 Nov; 4(1):80. PubMed ID: 32025904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
    Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study.
    Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M
    Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.